Andrzej Jakubowiak
A5057911528- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Ubiquitin and proteasome pathways
- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- Cancer therapeutics and mechanisms
- HIV/AIDS drug development and treatment
- Cancer Mechanisms and Therapy
- Synthesis and Biological Evaluation
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Cell death mechanisms and regulation
- Quinazolinone synthesis and applications
- Sperm and Testicular Function
- Immunotherapy and Immune Responses
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Nuclear Structure and Function
- Glycosylation and Glycoproteins Research
- Research on Leishmaniasis Studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Synthesis and biological activity
University of Chicago
2015-2024
University of Chicago Medical Center
2015-2024
Palmetto Hematology Oncology
2024
University of Illinois Chicago
2011-2023
Emory University
2009-2023
Samsung Medical Center
2023
Sungkyunkwan University
2023
Tisch Hospital
2018
NYU Langone Health
2018
Mayo Clinic in Florida
2018
Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis poorly understood. Here we report the massively parallel sequencing 38 tumour genomes their comparison to matched normal DNAs. Several new unexpected oncogenic mechanisms were suggested by pattern somatic mutation across data set. These include genes involved in protein translation (seen nearly half patients), histone methylation, blood coagulation. In addition, a broader than anticipated role NF-κB signalling...
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and has shown efficacy in phase 1 2 study
The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible autologous stem-cell transplantation. Daratumumab has shown efficacy in standard-of-care regimens relapsed or refractory myeloma.
CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, durable responses at 12 months. Here, we present updated results 2 years after last patient (median follow-up [MFU] approximately 28 months), including analyses high-risk subgroups.Eligible had received ≥ 3 prior lines therapy or were double refractory to proteasome inhibitor...
Purpose In the ASPIRE study of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide plus (Rd) in patients with relapsed or refractory multiple myeloma, progression-free survival was significantly improved carfilzomib group (hazard ratio, 0.69; two-sided P < .001). This prespecified analysis reports final overall (OS) data updated safety results. Patients Methods Adults myeloma (one to three prior lines therapy) were eligible randomly assigned at a one-to-one ratio receive...
Abstract Chimeric antigen receptor (CAR) T-cell therapies are highly effective for multiple myeloma (MM) but their impressive efficacy is associated with treatment-related neurotoxicities in some patients. In CARTITUDE-1, 5% of patients MM reported movement and neurocognitive treatment-emergent adverse events (MNTs) ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen-targeted CAR therapy. We assessed the factors MNTs CARTITUDE-1. Based on common features, who experienced were...
8009 Background: Heavily pretreated patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated standard of care therapy have median overall survival (OS) ~12 months (mo). In the single-arm, phase 1b/2 CARTITUDE-1 study (NCT03548207), pts received a single infusion ciltacabtagene autoleucel (cilta-cel), CAR-T cell targeting BCMA. At final protocol-specified analysis (27.7-mo follow-up [MFU]), response rate (ORR) was 98%, 83% stringent complete (CR); 27-mo rates progression-free...
Abstract Multiple myeloma (MM) is a plasma cell malignancy expressing B maturation antigen (BCMA). Elranatamab, bispecific antibody, engages BCMA on MM and CD3 T cells. The MagnetisMM-1 trial evaluated its safety, pharmacokinetics efficacy. Primary endpoints, including the incidence of dose-limiting toxicities as well objective response rate (ORR) duration (DOR), were met. Secondary efficacy endpoints included progression-free survival (PFS) overall (OS). Eighty-eight patients with relapsed...
The hypothalamic hormone, GnRH, is released and transported to the anterior pituitary in a pulsatile manner, where it binds specific high-affinity receptors regulates gonadotropin biosynthesis secretion. frequency of GnRH pulses changes under various physiological conditions, varying pulse frequencies have been shown regulate differentially secretion LH FSH expression alpha, beta, beta subunit genes vivo. We demonstrate differential effects vitro superfused primary monolayer cultures rat...
The recent isolation of cDNAs encoding the rat pituitary gonadotropin-releasing hormone receptor (GnRHR) allows studies regulation synthesis GnRHR and its relationship to reproductive function. Analyses mRNA levels in vivo revealed a progressive increase 2.0 +/- 0.2-fold after ovariectomy (OVX) 5.2 1.3-fold castration (CAST) (21 days post-operative), compared intact adult female male controls, respectively. Replacement therapy with 17 beta-estradiol benzoate 21-day post-OVX rats resulted...